Bank Of New York Mellon Corp Aurinia Pharmaceuticals Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$5.94 - $11.27 $2.37 Million - $4.49 Million	398,565 New	398,565 $4.37 Billion
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $1.66 Million - $3.29 Million	403,834 New	403,834 $1.74 Million
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $238,787 - $444,231	35,854 Added 9.65%	407,351 $3.06 Million
Q2 2022 Aug 15, 2022	BUY	$8.95 - $12.8 $3.32 Million - $4.76 Million	371,497 New	371,497 $3.73 Million
Q3 2021 Nov 12, 2021	SELL	$10.93 - $23.55 $154,878 - $333,703	-14,170 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$10.0 - $14.52 $380,300 - $552,195	-38,030 Reduced 72.85%	14,170 $183,000
Q1 2021 May 13, 2021	SELL	$12.3 - $18.73 $82,176 - $125,135	-6,681 Reduced 11.35%	52,200 $677,000
Q4 2020 Feb 09, 2021	BUY	$12.94 - $16.05 $761,920 - $945,040	58,881 New	58,881 $814,000
Q1 2018 May 15, 2018	SELL	$4.85 - $5.99 $56,536 - $69,825	-11,657 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$4.53 - $7.09 $52,806 - $82,648	11,657	11,657 $52,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.